Why Omeros Corporation Shares Crashed
Alex Planes, The Motley Fool - Motley Fool - 1 hr 40 mins ago
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Omeros Corporation are trading 9% lower...
Omeros Corporation Reports First Quarter 2014 Financial Results
PR Newswire - Mon May 12, 3:05PM CDT
Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and financial results for the first quarter of 2014, which include:
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Alcohol Addiction - Pipeline Review, H1 2014: Includes 17 Company and 33 Drug Profiles
M2 - Mon May 12, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fhvv9/alcohol_addiction) has announced the addition of the "Alcohol Addiction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcohol Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alcohol Addiction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alcohol Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Addex Therapeutics - Adial Pharmaceuticals, LLC - AllTranz, Inc. - Bionex Pharmaceuticals LLC - Curemark, LLC - D&A Pharma SAS - Eli Lilly and Company - Euthymics Bioscience, Inc. - Heptares Therapeutics Ltd. - Johnson & Johnson - Kyorin Pharmaceutical Co., Ltd. - Omeros Corporation - Pfizer Inc. - Sun Pharmaceutical Industries Limited - Tekmira Pharmaceuticals Corp. - VM Discovery, Inc. Drug Profiles: - baclofen - ibudilast - aprepitant - ABT-436 - pioglitazone hydrochloride - OMS-403 - LY-2940094 - (topiramate ondansetron) - ondansetron - sodium oxybate IR - OMS-405 - GET-73 - ivermectin - oxytocin - baclofen ER - JNJ-39220675 - amitifadine - ADX-71441 - OMS-527 - TKM-ALDH2 - Small Molecule Targeting Orexin 1 - CM-1212 - JNJ-31020028 - SLV-330 - Drugs to Inhibit Histone Deacetylase for CNS Disorders - JNJ-5234801 - VMD-2202 - Drug For Alcohol Addiction - Compound 1 - Small Molecule To Antagonize Ghrelin For Alcoholism For more information visit http://www.researchandmarkets.com/research/8f..._addiction
Traumatic Brain Injury - Pipeline Review, H1 2014: Includes 42 Company and 72 Drug Profiles
M2 - Mon May 12, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vqxgvm/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - ALSP, Inc. - Acorda Therapeutics, Inc. - Adamas Pharmaceuticals, Inc. - Allinky Biopharma - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Bionature E.A. Ltd. - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - D-Pharm Ltd. - Encore Therapeutics Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - Intellect Neurosciences, Inc. - Io Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - M's Science Corporation - MAPREG - MandalMed, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - NeuroHealing Pharmaceuticals Inc. - NeuroNascent, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Oxygen Biotherapeutics, Inc. Drug Profiles: - epoetin alfa - progesterone - progesterone - NeuroSTAT - Oxycyte - VAS-203 - NH-001 - NNZ-2566 - atorvastatin calcium - NeuroSTAT - glyburide - Allopregnanolone - VOLT-02 - SB-623 - RGS-2064 - DP-b99 - amantadine hydrochloride - Drug for Traumatic Brain Injury - MAP-4343 - Posiphen - MultiStem - Lpathomab - RGN-352 - cutamesine - INN-01 - NSI-189 - COG-1410 - AMR-001 - NSI-566 - LB-201 For more information visit http://www.researchandmarkets.com/research/vq...atic_brain
Cognitive Impairment - Pipeline Review, H1 2014: 40 Companies and 82 Drugs Profiled
M2 - Thu May 08, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kz65z/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AGY Therapeutics, Inc. - AbbVie Inc. - Amarantus Bioscience Holdings, Inc. - Avineuro Pharmaceuticals, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celon Pharma Sp. z o.o. - CoMentis, Inc. - D-Pharm Ltd. - Dart NeuroScience LLC - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Heptares Therapeutics Ltd. - Intra-Cellular Therapies, Inc. - Merck & Co., Inc. - Merz Pharmaceuticals GmbH - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeuroDerm Ltd. - Novartis AG - Octapharma AG - Omeros Corporation - Pacific Northwest Biotechnology, LLC - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - QR Pharma, Inc. - SK Biopharmaceuticals Co., Ltd. Drug Profiles: - MK-8931 - idursulfase - AQW-051 - GTS-21 - AVN-211 - tesamorelin acetate - eltoprazine - CHF-5074 - immune globulin (human) - ABT-126 - Peptide T - citicoline sodium - erteberel - ladostigil tartrate - sodium oligomannurarate - DAOI-B - levetiracetam - mifepristone - F-03 - Posiphen - GSK-933776 - roflumilast - ABT-560 - TTP-4000 - ITI-214 - HTL-9936 - SKL-15508 - BMS-933043 - AN-761 - PH-15 For more information visit http://www.researchandmarkets.com/research/4kz65z/cognitive
Drug Addiction - Pipeline Review, H1 2014: 17 Company and 34 Drugs Profiled
M2 - Wed May 07, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp6lcx/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Addex Therapeutics - Alkermes Plc - Aphios Corporation - Biotie Therapies Corp. - Camurus AB - Curemark, LLC - D&A Pharma SAS - Embera NeuroTherapeutics, Inc. - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lightlake Therapeutics Inc. - LondonPharma Ltd - Omeros Corporation - Rottapharm|Madaus - SK Biopharmaceuticals Co., Ltd. - Savant HWP, Inc. - Teva Pharmaceutical Industries Limited Drug Profiles: - nepicastat hydrochloride - ibudilast - buprenorphine hydrochloride - SKL-N05 - Butyrylcholinesterase - candesartan cilexetil - baclofen ER - ketamine hydrochloride - (oxazepam metyrapone) - (samidorphan buprenorphine hydrochloride) - LT-22 - ASB - methadone - dronabinol - ADX-88178 - ADX-71441 - OMS-527 - Vaccine For Cocaine Addiction - Cocaine Addiction Vaccine - MH-6 Vaccine - MH-2 [R] Vaccine - Ibogaine Analog - 5HT2 Modulators for CNS and Metabolic Disorders - CM-1212 - methoxycoronaridine - ICKLH-SMO9 Vaccine - N-acetylcystein MGluR5 Antagonist - CR-5542 Series - Small Molecules to Inhibit DAT and SERT for CNS Disorders - Triazole Compounds For more information visit http://www.researchandmarkets.com/research/sp..._addiction
Technical Data on Top Gainers -- Research on MeetMe, Cerus, Durect, and Omeros
PR Newswire - Tue May 06, 12:38PM CDT
The US markets saw a positive sentiment on Monday, May 05, 2014, with the NASDAQ Composite closing at 4,138.06, up 0.34%, the Dow Jones Industrial Average ending the session at 16,530.55, up 0.11% and the S&P 500 edging 0.19% higher to finish the trading session at 1,884.66. The session saw a positive impact from Energy, Health Care and Utilities sectors along with a drag from Financials and Consumer Staples sectors. A number of stocks saw large movements, including MeetMe Inc. (NASDAQ: MEET), Cerus Corporation (NASDAQ: CERS), Durect Corporation (NASDAQ: DRRX) and Omeros Corporation (NASDAQ: OMER). Free technical research on MEET, CERS, DRRX and OMER can be downloaded upon signing up at:
Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcl2wq/opium_opioid) has announced the addition of the "Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects Companies Involved in Therapeutics Development - BioDelivery Sciences International, Inc. - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - IntelGenx Corp. - Catalyst Pharmaceutical Partners, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - (buprenorphine naloxone) - TA-CD - OMS-403 - buprenorphine hydrochloride - RBP-6300 - OMS-405 - MAL - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Ibogaine Analog - Heroin Vaccine - FP-004 - INT-0027 - methadone IR - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction For more information visit http://www.researchandmarkets.com/research/bc...ium_opioid
Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9rpd7/bipolar_disorder) has announced the addition of the "Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Dainippon Sumitomo Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Neurocrine Biosciences, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Delpor, Inc. - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - lurasidone hydrochloride - lurasidone hydrochloride - cariprazine - aripiprazole - quetiapine fumarate ER - ramelteon - Icariin - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - epoetin alfa - simvastatin - ketamine hydrochloride - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug For Cancer And Neurodegenerative Disease - lurasidone hydrochloride - Small Molecules for CNS Disorders - SKL-PSY - NP-202 - paliperidone - ebselen - GSK-3 Inhibitors for CNS and Metabolic disorders - risperidone - paliperidone - CNV-1061436 - KP-303 - GPR78 Antagonist for Bipolar Disorder and Schizophrenia - Small Molecule Targeting GPR50 for CNS and Metabolic Disorders - Ketamine Metabolites - Peptides For Bipolar Disorder - BRD-K98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/s9...r_disorder
Global Binge Eating Disorder therapeutics Pipeline Review 2014 - Analysis of 5 Companies & 7 Drug Profiles
M2 - Wed Apr 23, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wz9gnj/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Binge Eating Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Binge Eating Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Binge Eating Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Binge Eating Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Teva Pharmaceutical Industries Limited - Shire Plc - Omeros Corporation - Heptares Therapeutics Ltd. - Lightlake Therapeutics Inc. Drug Profiles - armodafinil - lisdexamfetamine dimesylate - bupropion hydrochloride - erythromycin propionate - LT-12 - OMS-527 - Small Molecule Targeting Orexin 1 For more information visit http://www.researchandmarkets.com/research/wz...nge_eating
Will St. Jude Medical (STJ) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:32PM CDT
Our proven model does not conclusively show that St. Jude Medical is likely to beat earnings this quarter.
Omeros to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Mon Apr 07, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 13th Annual Needham Healthcare Conference in New York later this week. The presentation is scheduled for Wednesday, April 9, 2014 at 3:00 p.m. EDT.
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Apr 03, 8:03AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for The Medicines Company , Omeros Corp. , Opko Health and VIVUS, . FDA accepts The Medicines Company's Biologic License Application for Fibrocaps ...
Omeros Invited to Present on OMS824 Phase 2 Clinical Program at the Schizophrenia International Research Conference
PR Newswire - Tue Apr 01, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced that the company was invited by the organizers of the 2014 Biennial Conference of the Schizophrenia International Research Society (SIRS) to make an oral presentation on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition. The SIRS Conference will take place in Florence, Italy April 5-9. The Omeros presentation is entitled "Early Clinical Results of the Phosphodiesterase 10 Inhibitor OMS643762 in Development for the Treatment of Schizophrenia and Huntington's Disease" and is scheduled for Sunday April 6 during the pharmaceutical pipeline session. OMS643762 is the reference name for OMS824 in the company's clinical development program.
Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register
Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference
PR Newswire - Fri Mar 21, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BioCentury Future Leaders in the Biotech Industry Conference in New York next week. The presentation is scheduled for Friday, March 28, 2014 at 9:00 a.m. EDT.
Omeros Closes $40.25 Million Public Offering of Common Stock
PR Newswire - Wed Mar 19, 4:19PM CDT
Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors prior to the opening of the market on March 14, 2014, relating to the sale of 3,500,000 shares of its common stock at a price of $11.50 per share for gross proceeds of approximately $40.25 million. The closing included the sale of 456,521 shares of common stock sold pursuant to the overallotment option granted by Omeros to the underwriters, which the underwriters exercised in full. After deducting underwriting discounts and other estimated offering expenses, Omeros will receive net proceeds from the transaction of approximately $37.8 million.
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 14, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: